Drug Investigation

, Volume 2, Issue 4, pp 203–207 | Cite as

Comparative Double-Blind Multicentre Study of Single-Dose Pefloxacin and Amoxicillin Plus Probenecid for Treatment of Acute Uncomplicated Gonorrhoea

  • J. Dubois
  • C. St-Pierre
  • C. Olivier
  • B. Clecner
  • T. W. Austin
  • R. Phillips
Original Research Article


In a double-blind, randomised multicentre study, 129 patients (92 males, 37 females) with culture proven acute uncomplicated genital gonorrhoea were given single oral doses of either Pefloxacin 800mg (n = 65) or amoxicillin 3.0g plus probenecid 1.0g (n = 64). Data from 36 patients (19 Pefloxacin and 17 amoxicillin plus probenecid) were not évaluable. All 146 strains of Neisseria gonorrhoeae isolated from evaluable patients were sensitive to Pefloxacin whereas 139 of 146 were sensitive to penicillin (statistically significant at p < 0.05, binomial test).

84% of gonococcal infections involved only a genital site whereas implication of other sites was observed in 11% of patients; 4% of the patients were asymptomatic carriers of infected participants. Cure (negative post-treatment culture) rates were 100% (65/65) in pefloxacin-treated patients and 94% (60/64) in the amoxicillin plus probenecid group: the 4 treatment failures were 3 men with positive N. gonorrhoeae urethral cultures and a woman with a positive throat culture. Postgonococcal urethritis was observed in 9 pefloxacin and 4 amoxicillin plus probenecid-treated patients. 18% of pefloxacin-treated patients and 15% of amoxicillin plus probenecid-treated patients presented drug-related adverse events consisting mainly of gastrointestinal (nausea, diarrhoea) or CNS (headache) disturbances of mild intensity. Two amoxicillin plus probenecid patients presented post-treatment Candida albicans vaginitis requiring antifungal therapy. In conclusion, results from this study indicate that a single oral 800mg dose of Pefloxacin can be considered as well tolerated and as effective as the amoxicillin plus probenecid combination for the treatment of acute uncomplicated gonorrhoea.


Amoxicillin Probenecid Chlamydia Trachomatis Pefloxacin Neisseria Gonorrhoeae 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Auckenthaler R, Michea-Hamzehpour M, Pechère JC. In vitro activity of newer quinolones against aerobic bacteria. Journal of Antimicrobial Chemotherapy 17 (Suppl. B): 29–36, 1986PubMedGoogle Scholar
  2. Barry AL, Thronsberry C. Susceptibility tests; diffusion test procedures. In Lennette et al. (Eds) Manual of clinical microbiology, 4th ed., pp. 978–987, American Society for Microbiology, Washington, DC, 1985Google Scholar
  3. Editorial. Treatment of sexually transmitted diseases. Medical Letter on Drugs and Therapeutics 28: 23–28, 1986Google Scholar
  4. Editorial. Treatment of sexually transmitted diseases. Medical Letter on Drugs and Therapeutics 32: 5–10, 1990Google Scholar
  5. Garrell JB, Thabaut A, Grossetête G, Forestier JF, Normand P. Efficacy and safety of Pefloxacin in male gonococcal urethritis. Abstract P54.6/4-10. 13th International Congress of Chemotherapy, Vienna, August 28 to September 2, 1983Google Scholar
  6. Hooper DC, Wolfson JA. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrobial Agents and Chemotherapy 33: 1662–1667, 1989PubMedCrossRefGoogle Scholar
  7. Ridgway GL. Antimicrobial chemotherapy of chlamydial infection: where next? European Journal of Clinical Microbiology 5: 550–553, 1986PubMedCrossRefGoogle Scholar
  8. Schacter J. Chlamydiae (Psittacosis — lymphogranuloma venereum — trachoma group). In Lennette et al. (Eds) Manual of clinical microbiology, 4th ed., pp. 856–862, American Society for Microbiology, Washington, DC, 1985Google Scholar
  9. Schoenknecht FD, Sabath LD, Thornsberry C. Susceptibility tests: special tests. In Lennette et al. (Eds) Manual of clinical microbiology, 4th ed., pp. 1000–1008, American Society for Microbiology, Washington, DC, 1985Google Scholar
  10. Tillement JP, Barré J, Houin G. Dose dependent pharmacokinetic studies of Pefloxacin, a new antibacterial agent, in humans. Journal of Pharmaceutical Sciences 73: 1379–1382, 1984PubMedCrossRefGoogle Scholar
  11. Van Roosbroeck RJ, Provinciael DR, Van Caekenberghe DL. Activity of the newer quinolones against Chlamydia trachomatis. British Journal of Venereal Diseases 60: 350, 1984PubMedGoogle Scholar
  12. Whittington WL, Knapp JS. Trends in resistance of Neisseria gonorrhoeae to antimicrobial agents in the United States. Sexually Transmitted Diseases 15: 202–210, 1988PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1990

Authors and Affiliations

  • J. Dubois
    • 1
  • C. St-Pierre
    • 1
  • C. Olivier
    • 2
  • B. Clecner
    • 3
  • T. W. Austin
    • 4
  • R. Phillips
    • 5
  1. 1.Centre Hospitalier Hôtel-Dieu de SherbrookeSherbrookeCanada
  2. 2.Clinique L’ActuelMontréalCanada
  3. 3.Hôtel-Dieu de Saint-JérômeSaint-JérômeCanada
  4. 4.Victoria General HospitalLondonCanada
  5. 5.Rhône-Poulenc Pharma Inc.MontréalCanada

Personalised recommendations